News

Preliminary Data to be Presented Evaluating ⁹⁹ᵐTc-Maraciclatide as a New Imaging Marker for Endometriosis

19/01/2024

London, UK, 19th January 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that an abstract on the preliminary data from the first cohort of patients in the “Detecting Endometriosis expressed integrins using technetium-99m” imaging (DETECT) study, has been accepted for oral presentation at the Society for Reproductive Investigation (SRI) annual meeting taking place from 12-16 March 2024 in Vancouver, Canada.

View News Article

Development of A Deep Learning Approach for Analysing Scans of Rheumatoid Arthritis Patients using ⁹⁹ᵐTc-Maraciclatide Presented at the IEEE Nuclear Science Symposium and Medical Imaging Conference 2023

08/11/2023

London, UK, 8 November 2023. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that a poster is being presented at the Institute of Electrical and Electronics Engineers Nuclear Science Symposium and Medical Imaging Conference 2023 taking place from 4 to 11 November in Vancouver, Canada.

View News Article

The Development of a Deep Learning Model to Classify Inflammation from ⁹⁹ᵐTc-Maraciclatide Scans Presented at the BNMS Autumn Meeting 2023

31/10/2023

London, UK, 31 October 2023. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that a poster titled “Automatic Classification of Inflamed Joint Regions in Rheumatoid Arthritis using Deep Networks with ⁹⁹ᵐTc-Maraciclatide Imaging” is being presented at the British Nuclear Medicine Society meeting taking place on 31 October in London.

View News Article

AI methods for automated identification of regions of inflammation from ⁹⁹ᵐTc-Maraciclatide imaging presented at the World Molecular Imaging Congress 2023

9/9/2023

London, UK, 9 September 2023. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that a poster titled “Automatic segmentation of regions of inflammation using deep neural networks for ⁹⁹ᵐTc-Maraciclatide gamma camera imaging of rheumatoid arthritis” is being presented at the World Molecular Imaging Society meeting taking place from 5 to 9 September in Prague, Czech Republic.

View News Article

Icahn School of Medicine at Mount Sinai commences clinical testing with Seracam®

6/9/2023

London, UK and New York, USA, 6 September 2023. Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing Seracam®, a portable hybrid gamma-optical camera for medical imaging, and the Icahn School of Medicine at Mount Sinai, a ground-breaking leader in medical education, today announce the start of clinical testing using the Seracam® camera.

View News Article

James Kaufman appointed as Chief Commercial Officer

20/06/2023

London, UK, 20 June 2023. Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medical technology company developing Seracam®, a portable hybrid gamma-optical camera for medical imaging, today announces the appointment of James Kaufman as Chief Commercial Officer. James brings almost thirty years’ experience in the global healthcare and molecular imaging industry and will be responsible for leading on the commercialisation of Seracam®, reporting to Chief Executive, Mark Rosser.

View News Article

First US site commences clinical testing of Seracam®

8/6/2023

London, UK, 8 June 2023. Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing a portable hybrid gamma-optical camera for medical imaging, today announces the start of clinical testing using the Seracam® camera at its first site in the United States. This is the second site to commence an investigator sponsored study comparing gamma images obtained using Seracam® with those obtained with a current state-of-the-art gamma camera for nuclear medical imaging, from the same patient on the same day.

View News Article

Initial Seracam® characterization results presented at BNMS Spring Meeting, Harrogate

22/05/2023

London, UK, 22 May 2023. Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing a portable hybrid gamma/optical camera for medical imaging, announces that an abstract titled ‘Initial characterization of the Seracam: a small-footprint gamma-optical camera, with fully automated collimator changing capabilities’ is being presented in a poster presentation at the British Nuclear Medicine Society (BNMS) Spring meeting taking place from 22-24 May 2023, in Harrogate, UK.

View News Article

First clinical testing of Seracam® commences at the University of Malaya

17/05/2023

London, UK, 17 May 2023. Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing a portable hybrid gamma-optical camera for medical imaging, and the University of Malaya, today announce the start of clinical testing using the Seracam® camera.

View News Article

Seracam® to be presented at Parathyroid Symposium 2023: Oral presentation on qualitative and quantitative capabilities and novel features of Seracam®

24/02/2023

London, UK, 24 Feb 2023. Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing a portable hybrid gamma/optical camera for medical imaging, today announces that an abstract titled ‘Seracam: A first look at a new portable gamma camera’ has been selected for oral presentation at the 5th Symposium on Parathyroid Fluorescence taking place 23-24 February 2023 in Geneva, Switzerland. Abstract 17 is available here.

View News Article

Initial Seracam® characterization results presented at Cancer Diagnosis Network Theranostics Workshop

22/11/2022

London, UK, 22 Nov 2022. Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing a portable hybrid gamma/optical camera for medical imaging, today announces that an abstract titled ‘Initial characterization of the Seracam: a small-footprint gamma-optical camera, with fully automated collimator changing capabilities’ has been selected for poster presentation at the Science and Technology Facilities Council funded, Cancer Diagnosis Network Theranostics Workshop on 22 November 2022, in London, UK.

View News Article

Generative Modelling methods for ⁹⁹ᵐTc-Maraciclatide presented at the Institute of Electrical and Electronics Engineers (IEEE) Medical Imaging Conference 2022

10/11/2022

London, UK, 10 Nov 2022. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), the clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that an abstract titled ‘Single-Shot Generative Modelling for ⁹⁹ᵐTc-Maraciclatide Imaging’ is being presented today at the IEEE Medical Imaging Conference taking place 5-12 November in Milan, Italy.

View News Article

Serac Healthcare Partners with University of Oxford to Evaluate the Potential of ⁹⁹ᵐTc-Maraciclatide to Diagnose Endometriosis Non-Invasively

07/06/2022

Serac Healthcare Ltd is working with the University of Oxford to investigate whether an experimental image marker (⁹⁹ᵐTc-maraciclatide) that binds to areas of inflammation can be used to visualise endometriosis using a 20-minute scan.

View News Article (PDF)

James McCutcheon FCCA, Appointed Chief Financial Officer

01/11/2021

Please join us in welcoming James to the Serac Life Sciences team. James is an experienced commercial and finance director with over 30 years’ experience in the pharmaceutical and medical device sectors, having held senior finance positions in both large multinationals, as well as smaller fast growing SMEs.

Julie Davis, Appointed Head of Quality Management

01/08/2020

Please join us in welcoming Julie to the Serac Life Sciences team as Head of Quality Management. Julie’s career has been spent in life science and radiopharmaceutical drug discovery, most recently consulting with biotech start-ups including leading the development and implementation of operational processes and quality systems.

Jon Barnett PhD, Appointed Head of CMC and Supply Chain

06/07/2020

We are pleased to announce that Jon has joined Serac Healthcare Limited as Head of CMC and Supply Chain. With over 20 years’ experience on radiopharmaceutical and biopharmaceutical product development and commercial supply, Jon has extensive experience of leading global functional and cross-functional project / operational teams to deliver new products and life cycle improvements.

Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress 2020

01/06/2020

Results from a Phase II study evaluating the potential of 99mTc-maraciclatide to image synovial inflammation at the whole-body level will be presented at the European League Against Rheumatism (“EULAR”) Congress 2020. The oral presentation is titled, “IMAGING NEOANGIOGENESIS IN RHEUMATOID ARTHRITIS (INIRA): WHOLE-BODY SYNOVIAL UPTAKE OF A 99MTC-LABELLED RGD PEPTIDE IS HIGHLY CORRELATED WITH POWER DOPPLER ULTRASOUND” and will be delivered by Dr Laura Attipoe, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.

Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 110

Session: Diagnostics and imaging procedures (Oral Presentations)

View News Article

Druin Burch FRCP, Appointed Chief Scientific Officer (CSO)

01/05/2020

Serac Life Sciences continues to strengthen its management team with the appointment of Dr Druin Burch as Chief Scientific Officer (CSO). Druin is a Consultant Physician at the Oxford University Hospitals NHS Trust, and has three decades experience as a clinician, scientist and writer in the field of developing and testing medical technology.

Abstract for Presentation at the American Congress of Rheumatology (ACR) Congress 2019

07/11/2019

Results from an interim analysis of the first 25 patients enrolled in a study evaluating the potential of 99mTc-maraciclatide to image synovial inflammation at the whole-body level will be presented at the American College of Rheumatology (ACR) Congress. The poster is titled, “IMAGING NEOANGIOGENESIS IN RHEUMATOID ARTHRITIS (INIRA): WHOLE-BODY SYNOVIAL UPTAKE OF A 99MTC-LABELLED RGD PEPTIDE IS HIGHLY CORRELATED WITH POWER DOPPLER ULTRASOUND” and will be presented by Dr Laura Attipoe, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.

Date: Sunday, November 10, 2019

Session Title: Imaging Of Rheumatic Diseases Poster I

Session Time: 9:00AM-11:00AM

View News Article

Serac Imaging Systems to launch hybrid gamma optical camera

01/07/2019

Serac Imaging Systems, based in Thames Ditton, is to launch an innovative, new hybrid Gamma Optical camera for medical applications. The new system is scheduled to be available from 2021 and will be portable, smaller, easier to use and more cost effective than anything that exists on the market today. It will bring the huge potential benefits of molecular imaging to patients whether in operating room, an intensive care unit, a physician’s office or even a remote village in the developing world.

Serac Imaging Systems to develop a compact, hybrid optical/gamma camera which will be portable, smaller, easier to use and more cost effective than anything that exists on the market today.

27/06/2019

Serac Imaging Systems Limited (SIS), a wholly-owned subsidiary of Serac Life Sciences Limited (SLS), is developing and commercialising a novel, compact, portable, hybrid gamma/optical camera (HGC) the IP for which has been exclusively licensed from a group of universities led by the University of Leicester.

View News Article (PDF)

Pat Butler, Joins as Board Observer and Advisor.

10/06/2019

Pat, a qualified Chartered Accountant, is a director of Hikma Pharmaceuticals, Chairman of Aldermore Bank and was formerly a Senior Director at McKinsey & Co. He is also a Governor of the British Film Institute and a trustee of the Resolution Foundation.

Serac Healthcare founded to develop a molecular imaging agent to help rheumatologists manage treatment decisions in their patients with rheumatoid arthritis

27/06/2018

Serac Life Sciences Limited (SLS) announces the formation of a new company, Serac Healthcare Limited (SHC), which will develop and commercialise a novel molecular imaging agent for the detection of disease activity in rheumatoid arthritis (RA). SHC, a wholly-owned subsidiary of SLS, has acquired the molecular imaging agent maraciclatide from GE Healthcare. The goal of the company is to enable rheumatologists to “see disease activity” in the joints, informing clinicians and helping them deliver personalised care to their patients.

View News Article (PDF)